The immunomodulatory properties of mesenchymal stem cells [MSCs] are being tested to relieve the symptoms of asthma - airway inflammation which results in difficulty breathing. Asthmatic symptoms are caused by the body’s hypersensitive immune response to inhaling harmless allergens that trigger inflammation, which constricts airways and causes breathing to become extremely difficult, requiring an inhaler to counteract the inflammation. When administered in an animal model, mesenchymal stem cells (the same type of stem cells found in teeth) have successfully produced anti-inflammatory factors and neuropeptides that counteracted airway hypersensitivity and the production of pro-inflammatory receptors.
With clinical trials expected to be underway soon, the successful application of this stem cell based treatment has the potential to benefit the hundreds of millions of people suffering from asthma worldwide. Current asthma sufferers require constant vigilance and rely on inhalers to save their lives in the case of severe asthmatic episodes. In a person with asthma, the airway inflammation can be triggered by hundreds of allergens, and in severe cases, the airway constriction can cause suffocation. Current treatments merely handle the symptoms of asthma and currently there is no cure. In addition, 10% of current asthmatic patients show evidence of [inhaler] drug resistance and are at heightened risk. Utilizing MSCs, the researchers look to provide a more natural option that seeks to address the root cause of the problem.
Successful clinical trials would point the way to other immunomodulation applications, thus accelerating and broadening applications to treat a wider variety of respiratory problems. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.